An investigation on behalf of investors of Hyperion Therapeutics Inc (NASDAQ:HPTX) in connection with the proposed takeover was announced and NASDAQ:HPTX stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 04/07/2015 -- An investigation on behalf of investors, who currently hold shares of Hyperion Therapeutics Inc (NASDAQ:HPTX), was announced concerning whether the takeover of Hyperion Therapeutics Inc by Horizon Pharma plc for $46.00 per share is unfair to NASDAQ:HPTX stockholders.
Investors who purchased shares of Hyperion Therapeutics Inc (NASDAQ:HPTX) and currently hold any of those NASDAQ:HPTX shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain officers and directors of Hyperion Therapeutics Inc breached their fiduciary duties owed to NASDAQ:HPTX investors in connection with the proposed acquisition.
On March 30, 2015, Horizon Pharma plc and Hyperion Therapeutics, Inc. (NASDAQ: HPTX) announced they have entered into an agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Hyperion Therapeutics Inc's common stock for $46.00 per NASDAQ:HPTX share in cash or approximately $1.1 billion on a fully diluted basis.
However, given that at least one analyst has set the high target price for NASDAQ:HPTX shares at $51.00 per share, the investigation concerns whether the offer is unfair to NASDAQ:HPTX stockholders. More specifically, the investigation concerns whether the Hyperion Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Hyperion Therapeutics Inc reported that its annual total Revenue rose from $42.20 million in 2013 to $113.58 million in 2014. Shares of Hyperion Therapeutics Inc (NASDAQ:HPTX) grew from slightly above $20 in early 2014 to as high as $44.13 per share on March 27, 2015.
On April 2, 2015, NASDAQ:HPTX shares closed at $45.89 per share.
Those who are current investors in Hyperion Therapeutics Inc (NASDAQ:HPTX) shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com